TABLE 4.
Multiple Cox regression analysis of AAPR in patients with advanced NSCLC
| AAPR | N | With outcomes N (%) | Nonadjusted | P value | Adjust I | P value | Adjust II | P value |
|---|---|---|---|---|---|---|---|---|
| Continuous | 808 | 529 | 0.44 (0.28, 0.67) | .0002 | 0.47 (0.29, 0.74) | .0014 | 0.52 (0.30, 0.88) | .0151 |
| Tertile | ||||||||
| Low | 266 | 187 (70.3%) | 1.0 | 1.0 | 1.0 | |||
| Medium | 259 | 160 (61.8%) | 0.81 (0.66, 1.00) | .0525 | 0.77 (0.61, 0.97) | .0277 | 0.77 (0.58, 1.03) | .0756 |
| High | 283 | 182 (64.3%) | 0.63 (0.51, 0.77) | <.0001 | 0.65 (0.52, 0.81) | .0001 | 0.59 (0.45, 0.78) | .0001 |
| P trend | 0.23 (0.12, 0.45) | <.0001 | 0.26 (0.13, 0.53) | .0002 | 0.20 (0.08, 0.45) | .0001 | ||
Nonadjusted model adjusted for: None.
Adjust I model adjusted for: age, gender, clinical stage, smoking history, ECOG‐PS, pathology.
Adjust II model adjusted for: age, gender, clinical stage, smoking history, ECOG‐PS, pathology, liver metastasis, lung metastasis, bone metastasis, brain metastasis, malignant pleural effusion, number of metastatic organ, number of treatment lines, EGFR mutation status, ALK mutation status, first‐line regiments.